Identification of SEC61G as a Novel Prognostic Marker for Predicting Survival and Response to Therapies in Patients with Glioblastoma

首页 > 成果 > 详情

认领

导出

Link by DOI

反馈

作者信息关键词期刊信息基础信息归属信息摘要

成果类型：

期刊论文

作者：

Liu, Bo;Liu, Jingping;Liao, Yuxiang;Jin, Chen;Zhang, Zhiping;...

通讯作者：

Cheng, Quan

作者机构：

[Liu, Bo; Liu, Jingping; Liao, Yuxiang; Jin, Chen; Cheng, Quan; Zhao, Jie; Zhang, Zhiping] Cent S Univ, Xiangya Hosp, Dept Neurosurg, Changsha, Hunan, Peoples R China.

[Liu, Kun; Huang, Hao] Hosp Hunan Univ Chinese Med, Peoples Hosp Hunan Prov 2, Dept Neurosurg, Changsha, Hunan, Peoples R China.

[Cao, Hui] Hosp Hunan Univ Chinese Med, Peoples Hosp Hunan Prov 2, Dept Psychiat, Changsha, Hunan, Peoples R China.

[Cheng, Quan] Cent S Univ, Xiangya Hosp, Dept Clin Pharmacol, Changsha, Hunan, Peoples R China.

通讯机构：

[Cheng, Quan] C

Cent S Univ, Xiangya Hosp, Dept Neurosurg, Changsha, Hunan, Peoples R China.

Cent S Univ, Xiangya Hosp, Dept Clin Pharmacol, Changsha, Hunan, Peoples R China.

语种：

英文

关键词：

Drug resistance;Glioblastoma;Prognosis;Radiotherapy

期刊：

Medical Science Monitor

ISSN：

1643-3750

年：

2019

卷：

页码：

3624-3635

DOI：

10.12659/MSM.916648

基金类别：

National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81703622]; China Postdoctoral Science FoundationChina Postdoctoral Science Foundation [2018M633002]; Hunan Provincial Natural Science Foundation of ChinaNatural Science Foundation of Hunan Province [2018JJ3838]

机构署名：

本校为其他机构

摘要：

Background: The survival and therapeutic outcome vary greatly among glioblastoma (GBM) patients. Treatment resistance, including resistance to temozolomide (TMZ) and radiotherapy, is a great obstacle for these therapies. In this study, we aimed to evaluate the predictive value of SEC61G on survival and therapeutic response in GBM patients.Material/Methods: Survival analyses were performed to assess the correlation between SEC61G expression and survival of GBM patients from the Cancer Genome Atlas (TCGA) and the Chinese Glioma Genome Atlas (CGGA...

反馈

产权有误：本人成果被他人认领

数据有误：数据基本信息有误

归属有误：成果的院系归属、机构署名归属有误

其他原因：

验证码：

看不清楚，换一个

确定

取消

成果认领

标题：

用户	作者	通讯作者	--
	请选择	请选择	--

确定

取消

Identification of SEC61G as a Novel Prognostic Marker for Predicting Survival and Response to Therapies in Patients with Glioblastoma

反馈

成果认领

提示

该栏目需要登录且有访问权限才可以访问